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UbiquitinationThe human telomeric protein TRF2 protects chromosome ends by facilitating their organization into
the protective capping structure. Here we show that the stability of TRF2 is regulated via modifica-
tion by the small ubiquitin-like modifiers (SUMO). TRF2 specifically interacts with and is sumoylated
by PIAS1 in mammalian cells. The proteasome inhibitor stabilizes SUMO-conjugated TRF2 without
affecting the level of unmodified TRF2, suggesting that SUMO conjugation is required for proteaso-
mal degradation of TRF2. We also show that RNF4, a mammalian SUMO-targeted ubiquitin ligase,
interacts with TRF2 in a SUMO-dependent manner and preferentially targets SUMO-conjugated
TRF2 for ubiquitination. Collectively, our data demonstrate that the PIAS1-mediated sumoylation
status of TRF2 serves as a molecular switch that controls the level of TRF2 at telomeres.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Telomeres are the specialized nucleoprotein complexes at the
ends of eukaryotic chromosomes, which are essential for chromo-
some integrity [1,2]. Mammalian telomeres consist of duplex tan-
dem TTAGGG repeats with 30 single-stranded G overhangs [3,4]
and are tightly associated with the six-protein complex shelterin,
thereby protecting chromosome ends from being recognized as
sites of DNA damage [5,6]. In addition to the shelterin complex,
telomeres are associated with a number of accessory factors that
are involved in DNA metabolism [7]. Although the precise mecha-
nism by which these factors act on telomeres remains to be seen,some accessory factors have been shown to be essential for
telomere protection [8,9].
The shelterin subunit telomeric repeat binding factor 2 (TRF2)
plays an essential role in protecting chromosome ends by facilitat-
ing their organization into the protective capping structure [10,11].
Functional inhibition of TRF2 induces uncapped or dysfunctional
telomeres, which is characterized by loss of telomere overhangs
and DNA damage responses at telomeres [12,13]. Post-
translational modifications of TRF2 including phosphorylation,
ubiquitination, methylation, poly(ADP-ribosyl)ation and acetyla-
tion have been shown to contribute to the maintenance of func-
tional telomeres [14]. TRF2 is phosphorylated in response to DNA
damage by an ATM-dependent pathway [15,16]. The phosphory-
lated form of TRF2 is not bound to telomeres and accumulates at
DNA damage sites. TRF2 is also methylated by protein arginine
methyltransferase, which regulates DNA-damage response at
telomeres [17]. TRF2 is modified by poly(ADP-ribose) polymerases
(PARP1 and PARP2), leading to reduction in TRF2 binding to telom-
eres [18,19]. In the case of ubiquitination, Siah1 has been identified
as an E3 ubiquitin ligase for TRF2 and is transcriptionally induced
by p53 [20]. Under the conditions inducing telomere dysfunction,
ATM-mediated activation of p53 activates Siah1, subsequently
leading to a reduction in the level of TRF2 through proteasomal
degradation.
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modifier (SUMO) to lysine residues of target proteins, is a reversi-
ble post-translational modification that can modify protein func-
tion by altering stability, localization, activity or protein–protein
interactions [21]. In vertebrates, three SUMO isoforms (SUMO-1,
SUMO-2 and SUMO-3) are encoded by three different genes [22].
Whereas mature SUMO-2 and SUMO-3 are nearly identical, they
differ significantly from SUMO-1. SUMO-2 and SUMO-3 contain
an internal sumoylation site that can be used to form SUMO chains
on target proteins [23]. In contrast, SUMO-1 serves as a chain-
terminator by linking a single molecule to lysine residues. It has
been shown that MMS21, a SUMO ligase that is a member of the
multi-subunit SMC5/6 complex, stimulates the sumoylation of
multiple subunits of the shelterin complex, including TRF1 and
TRF2 [24]. Inhibition of TRF2 sumoylation blocks the recruitment
of telomeres to promyelocytic leukemia (PML) bodies, termed
alternative lengthening of telomeres (ALT)-associated PML bodies
(APBs) [24]. Thus, sumoylation of TRF2 by MMS21 is important
for APB formation in ALT cells. Although sumoylation is not gener-
ally linked to the degradation of target proteins, some of SUMO-
conjugated proteins including PML, Sp1, HIF-2a and Rta are subject
to ubiquitination by SUMO-targeted ubiquitin ligases (STUbLs) and
proteasomal degradation [25–29]. Ring-finger protein 4 (RNF4) is a
mammalian STUbL that preferentially recognizes sumoylated tar-
get proteins through SUMO-interacting motifs (SIMs) [30].
In this study, we demonstrate that TRF2 interacts with and is
sumoylated by PIAS1. RNF4 targets SUMO-conjugated TRF2 for
ubiquitination, thereby decreasing the stability of TRF2. These find-
ings suggest that the PIAS1-mediated sumoylation status of TRF2
provides a molecular switch that controls the levels of TRF2 at
telomeres and represents a new pathway for maintaining func-
tional telomeres.2. Materials and methods
2.1. Cell culture and plasmids
The human embryonic kidney cell line HEK293, the human
breast cancer cell line MCF7 and the human osteosarcoma cell line
U2OS were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, 100 units/ml penicillin,
and 100 lg/ml streptomycin in 5% CO2 at 37 C. The expression
vectors for Flag-TRF2, Myc-PIAS1, and V5-RNF4 were constructed
by inserting the full-length cDNAs into pRK5-Flag, pRK5-Myc,
and pRK5-V5, respectively. The expression vectors for GST-TRF2
were constructed by cloning the full-length and truncated frag-
ments from the TRF2 cDNA into pGEX-4T-2 (Amersham Bio-
sciences). The V5-RNF4C132/135S and Myc-PIAS1C351S plasmids
were generated by site-directed mutagenesis using the Quick-
Change II kit according to the instructions of the manufacturer
(Stratagene). The Flag-TRF2DSUMO plasmid was a kind gift from
Dr. P.R. Potts (University of Texas Southwestern Medical Center,
U.S.A.) [24].
2.2. GST pull-down, immunoprecipitation, and immunoblotting
The expression vectors were transfected into cells using Lipo-
fectAMINE 2000 (Invitrogen) for 24 h followed by lysis. For GST
pulldown assay, lysates were precleared with glutathione-
Sepharose 4B (Amersham Biosciences) and incubated with
glutathione-Sepharose beads containing GST fusion proteins for
2 h at 4 C. For immunoprecipitation, lysates were preincubated
with protein A-Sepharose (Amersham Biosciences) and incubated
with primary antibodies precoupled with protein A-Sepharose
beads for 2 h at 4 C. Immunoprecipitation and immunoblottingwere performed using anti-Flag (Sigma), anti-Myc (Santa Cruz
Biotechnology), anti-V5 (Invitrogen), anti-HA (Santa Cruz Biotech-
nology), anti-TRF2 (Cell Signaling Technology), anti-PIAS1 (Santa
Cruz Biotechnology), anti-SUMO-1 (Sigma), anti-SUMO-2/3
(Abcam), anti-RNF4 (Sigma), and anti-actin (Sigma) antibodies as
specified. All the immunoblots are representatives of at least three
experiments that demonstrated the similar results.
2.3. Sumoylation assay
GST-TRF2, GST-PIAS1, GST-SUMO-1, GST-SAE1/2 and His-Ubc9
were expressed in bacteria and used for in vitro sumoylation assay.
The sumoylation assay was carried out in buffer (50 mM Tris–HCl,
pH 7.6, 5 mM MgCl2 and 2 mM ATP) containing SAE1/2 (150 ng),
Ubc9 (50 ng) and SUMO-1 (0.5 lg). The reactions were incubated
at 37 C for 1 h and separated on an 8% SDS–polyacrylamide gel
electrophoresis. Unmodified and SUMO-conjugated TRF2 were
visualized by immunoblotting using anti-TRF2 antibody. For His-
SUMO pull-down assay, HEK293 cells were co-transfected with
His-SUMO-1, HA-TRF2 and Myc-PIAS1 and lysed in a 6 M
guanidine hydrochloride-containing buffer as described previously
[31]. Lysates were added with His-select magnetic
Ni2+-nitrilotriacetate beads (Sigma) and incubated for 4 h at room
temperature. The eluted SUMO conjugates were analyzed by
immunoblotting using an anti-HA antibody.
2.4. Ubiquitination assay
Cells transfected by Flag-TRF2 and HA-ubiquitin expression
vectors were treated with 10 lM MG132 to inhibit proteasome
function and lysed in buffer (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% SDS, 10 mM NEM), followed by incubation with Ben-
zonase (Sigma) at 37 C for 15 min. Lyasates were boiled for
5 min and clarified by centrifugation at 14,000g for 20 min.
Lysates were diluted with dilution buffer (50 mM Tris–HCl, pH
7.5, 150 mM NaCl, 0.5% NP-40, 10 mM NEM) by 10-fold and then
subjected to immunoprecipitation with anti-Flag M2 affinity resins
(Sigma), followed by immunoblotting with anti-HA antibody to
illuminate ubiquitin-conjugated TRF2.
2.5. Immunofluorescence
Cells were grown on glass coverslips, fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 10 min
and permeabilized in 0.2% Triton X-100 in PBS for 20 min. Cells
were then blocked in PBS containing 5% bovine serum albumin
and incubated with anti-TRF2 (Cell Signaling Technology) and
anti-PML (Santa Cruz Biotechnology) antibodies overnight at 4 C.
After washing with PBS, cells were incubated with Alexa Flour
488 goat anti-rabbit immuoglobulin and Alexa Fluor 546 goat
anti-mouse immunoglobulin (Molecular Probes). DNA was stained
with 4,6-diamino-2-phenylindole (DAPI) (Vectashield; Vector Lab-
oratories). Immunofluorescence images were captured using a con-
focal laser-scanning microscope (Carl Zeiss).
2.6. RNA interference
The siRNA duplexes were transfected into HEK293 cells using
RNAiMax transfection reagent (Invitrogen). The siRNA target
sequences specific for PIAS1 were 50-GCGGAUCCAGACAGU-
GAAAUAGCUA-30 for siPIAS1-1 and 50-GCUGUAGACACAAGCUA-
CAUUAAUA-30 for siPIAS1-2. The siRNA target sequences specific
for Ubc9 were 50-CAAAAAAUCCCGAUGGCACTT-30 for siUbc9-1
and 50-GCAGAGGCCUACACGAUUUACTT-30 for siUbc9-2. The siRNA
target sequences specific for RNF4 were 50-GAAUGGACGUCUCAUC-
GUUUU-30 for siRNF4-1 and 50-UCCCAUCUGCAUGGACGGAUA-30
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TATGCCGTT-30) was used as a control and did not correspond to
any known gene in the data bases.
3. Results
3.1. Identification of PIAS1 as a TRF2-interacting factor
To identify TRF2-interacting factors, we screened a HeLa cell
cDNA library using the yeast two-hybrid system. With the full-
length TRF2 as bait, 28 positive clones were obtained and
sequenced. One of the isolated clones contained the cDNA encod-
ing PIAS1. PIAS1 has been shown to promote sumoylation of its
interacting proteins and modify protein function by altering cellu-
lar localization or protein–protein interactions [21]. Although the
functional importance of TRF2 sumoylation by MMS21 has been
reported [24], we are particularly interested in identification of
the SUMO E3 ligase that can interact with TRF2. To confirm the
direct interaction between TRF2 and PIAS1, we performed GST
pull-down experiments. GST-TRF2, but not the control GST, precip-
itated Flag-PIAS1 expressed in HEK293 cells, indicating that TRF2
interacts with PIAS1 in vitro (Fig. 1A). RAP1, which was shown to
interact with TRF2 [32], was used as a positive control. To deter-
mine whether TRF2 and PIAS1 associate in vivo, HEK293 cells were
co-transfected with Flag-TRF2 and Myc-PIAS1 expression vectors
and subjected to immunoprecipitation. Flag-TRF2 was detected in
anti-Myc immunoprecipitates when Myc-PIAS1 was expressed
(Fig. 1B). Likewise, Myc-PIAS1 was recovered in anti-Flag immuno-
precipitates when Flag-TRF2 was expressed. Endogenous PIAS1
was immunoprecipitated by endogenous TRF2 in HEK293 cells
(Fig. 1C), demonstrating that TRF2 interacts with PIAS1 in mam-
malian cells.
To map the region in PIAS1 that is responsible for TRF2 binding,
a series of PIAS1 deletion fragments were generated (Fig. 1D).
When HEK293 cells were co-transfected with Flag-TRF2 and vari-
ous Myc-PIAS1 fragments, full-length PIAS1 and its fragment con-
taining amino acid residues 301–450 bound to Flag-TRF2. These
results indicate that TRF2 interacts with the internal region con-
taining the RING finger domain in PIAS1. We next determined
the domain in TRF2 that interacts with PIAS1. TRF2 fragments were
fused to GST and used in the in vitro binding assay (Fig. 1E). GST-
GAR bound efficiently to Flag-PIAS1, whereas GST-Hinge had sub-
stantially reduced binding activity. By contrast, GST-TRFH and
GST-Myb had no detectable binding activity. These data suggest
that TRF2 may bind PIAS1 through the two distinct regions, but
the GAR domain has higher affinity for PIAS1 binding than the
hinge domain.
3.2. PIAS1 stimulates the sumoylation of TRF2
To investigate the involvement of PIAS1 in the sumoylation of
TRF2, we performed an in vitro sumoylation assay using purified
components. In the reactions that contained SUMO-activating E1
enzyme, Ubc9, SUMO-1 and ATP, the high molecular mass bands
were detected, suggesting that TRF2 is conjugated by SUMO-1
(Fig. 2A). Notably, TRF2 was conjugated by SUMO-1 without PIAS1,
suggesting that in vitro SUMO conjugation may not depend on E3
ligase activity. Similar findings were observed for the in vitro
sumoylation of p53 [33] and Rta [34]. However, the amounts of
SUMO-conjugated TRF2 species were slightly increased by the
addition of GST-PIAS1 (Fig. 2A). The sumoylated TRF2 bands were
undetectable if ATP was omitted. To examine whether PIAS1 con-
tributes to the sumoylation of TRF2 in vivo, HEK293 cells were
co-transfected with Flag-TRF2, Myc-PIAS1 and V5-SUMO-1 and
subjected to immunoprecipitation with anti-Flag antibody, fol-
lowed by immunoblotting with anti-V5 antibody. The sumoylationof TRF2 was barely detected when Flag-TRF2 and V5-SUMO-1 were
co-transfected. By contrast, overexpression of PIAS1 under the
same experimental conditions led to a marked increase in the
sumoylation of TRF2 (Fig. 2B). When the SUMO isopeptidase SENP1
was co-transfected, the amounts of sumoylated TRF2 species were
greatly reduced (Fig. 2B). To verify that the higher molecular
shifted bands are really sumoylated forms of TRF2, HEK293 cells
were transfected with HA-TRF2, Myc-PIAS1 and His-SUMO-1 and
lysed under denaturing condition. After purification of His-
SUMO-1 conjugated proteins using Ni2+-nitrilotriacetate (Ni–
NTA) beads, the eluted proteins were analyzed by immunoblotting
with anti-HA antibody. When Myc-PIAS1 was co-expressed,
sumoylated forms of HA-TRF2 were detected in the higher molec-
ular mass region of the HA-blot (Fig. 2C). By contrast, the C351S
mutation in PIAS1, which abolishes the SUMO ligase activity [35],
severely impaired the sumoylation of TRF2 (Fig. 2C) although this
mutation demonstrated a strong interaction with TRF2 (Suppl.
Fig. S1). These results suggest that PIAS1 is an E3 ligase for TRF2
sumoylation in mammalian cells.
To examine whether endogenous TRF2 is sumoylated by PIAS1,
His-SUMO-1 conjugates were purified from HEK293 cells express-
ing Myc-PIAS1, GFP-SENP1 and His-SUMO-1 using Ni–NTA beads
and analyzed by immunoblotting with anti-TRF2 antibody. The
amounts of sumoylated TRF2 were increased by overexpression
of Myc-PIAS1 but decreased by the presence of SENP1 (Suppl.
Fig. S2A). The use of a SUMO-1 mutant (SUMO-1DGG), which is
incapable of conjugation, reduced the amount of sumoylated
TRF2 (Suppl. Fig. S2B). There are several types of the PIAS1 family,
which share redundant functions but perform unique roles inde-
pendent of each other [36]. To examine which PIAS stimulates
the sumoylation of TRF2 by SUMO-1, HEK293 cells were co-
transfected with HA-TRF2, His-SUMO-1 and one of PIAS isoforms
and subjected to purification of His-SUMO-1 conjugates using
Ni–NTA beads, followed by immunoblotting with anti-HA anti-
body. Although all PIAS isoforms used in this study were compara-
bly expressed, PIAS1 efficiently catalyzed SUMO-1 conjugation to
TRF2 (Suppl. Fig. S3). PIASxa and PIASy were also able to sumoylate
TRF2 but to a lesser extent in comparison with PIAS1.
To examine the role of PIAS1 in a more physiological setting, the
expression of endogenous PIAS1 was depleted using a pool of small
interfering RNA (siRNA) duplexes in HEK293 and MCF7 cells
expressing Flag-TRF2 and V5-SUMO-1. PIAS1 depletion led to a
clear reduction in the levels of SUMO-1-conjugated TRF2 in both
cell lines (Fig. 2D), demonstrating that the specificity of TRF2
sumoylation by PIAS1 was not related to the cellular background.
These findings further support that PIAS1 stimulates the sumoyla-
tion of TRF2 in mammalian cells.
Three SUMO proteins designated SUMO-1, -2 and -3, have been
described in vertebrates [22]. Because TRF2 is modified by
SUMO-1, we wished to determine whether this protein is also
modified by SUMO-2 and -3. HEK293 cells were co-transfected
with Flag-TRF2 and one of V5-tagged SUMO paralogues and sub-
jected to immunoprecipitation with anti-Flag antibody. When
Myc-PIAS1 was co-expressed, Flag-TRF2 was modified by SUMO-
2 or SUMO-3 as efficiently as SUMO-1 (Fig. 2E). Note that the
amounts of SUMO-3 conjugates were higher in cells expressing
V5-SUMO-3 compared with cells expressing V5-SUMO-1 or V5-
SUMO-2 (Fig. 2E). This is likely due to higher expression level of
V5-SUMO-3. These results indicate that PIAS1 does not discrimi-
nate between SUMO-1 and SUMO-2/3.
3.3. SUMO-conjugated TRF2 is preferentially degraded by the
ubiquitin–proteasome system
Earlier studies indicated that some of SUMO-conjugated pro-
teins can be targeted for ubiquitin-dependent proteolysis [37].
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ity of TRF2. HEK293 cells expressing Flag-TRF2 and one of
V5-tagged SUMO paralogues were treated or untreated with the
proteasome inhibitor MG132 before lysis and subjected to
immunoprecipitation to detect SUMO-conjugated TRF2. Flag-
TRF2 modified by all three SUMO paralogues exhibited a strong
accumulation upon proteasome inhibition by MG132 (Fig. 3A).However, the stability of unmodified TRF2 was not affected by
proteasome inhibition. To further investigate the respective
contributions of endogenous SUMO-1 and SUMO-2/3 to the TRF2
degradation process, HEK293 cells expressing Flag-TRF2 were
subjected to immunoprecipitation with anti-Flag antibody,
followed by immunoblotting with anti-SUMO-1 and anti-SUMO-2/3
antibodies. Treating cells with MG132 caused the accumulation of
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manner (Fig. 3B). These results suggest that the three SUMOs are
all involved in triggering TRF2 degradation and that SUMO-
conjugated TRF2 is preferentially degraded by the ubiquitin–
proteasome system. Since the amounts of unmodified TRF2 werenot affected by MG132, we examined whether the higher molecular
shifted signals represent SUMO- and ubiquitin-conjugated forms of
TRF2. HEK293 cells were treated with MG132 and analyzed by
immunoblotting with anti-TRF2 antibody. The shifted signals were
detected when cells were treated with MG132 (Fig. 3C). We note
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unmodified TRF2 signals. Because of relatively small portion of
SUMO- and ubiquitin-conjugated TRF2, the total level of unmodi-
fied TRF2 seems unaffected.
We next determined whether SUMO-conjugated TRF2 is
ubiquitinated prior to proteasome-dependent degradation.
HEK293 cells were co-transfected with Flag-TRF2 and HA-
ubiquitin and subjected to immunoprecipitation. Anti-Flag
immunoprecipitates were probed with anti-HA antibody toilluminate ubiquitin-modified TRF2. Ubiquitin conjugates of
TRF2 were readily detected in the presence of MG132
(Fig. 3D). The amounts of ubiquitinated TRF2 were reduced by
overexpression of SENP1 in a dose-dependent manner. We also
showed that the amounts of ubiquitinated TRF2 were reduced
when endogenous Ubc9 was depleted using siRNA duplexes
(Fig. 3E). Taken together, these data support the idea that SUMO
conjugation could be a requirement for ubiquitin-dependent
proteasomal degradation of TRF2.
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RNF4
The observation that proteasome inhibition stabilizes SUMO-
conjugated TRF2 implies that TRF2 could be regulated by SUMO-
targeted ubiquitin ligases (STUbLs). Given that RNF4 has been
shown to associate with sumoylated proteins and target the pro-
teins for ubiquitin-dependent degradation [30], we investigated
the involvement of RNF4 in SUMO-dependent TRF2 degradation.
We first examined whether RNF4 interacts with TRF2. HEK293
cells were co-transfected with Flag-TRF2 and V5-RNF4 and sub-
jected to immunoprecipitation. Flag-TRF2 was detected in anti-
V5 immunoprecipitates when V5-RNF4 was expressed (Fig. 4A).
A mutant form of RNF4 (RNF4C132,135S), in which ubiquitin ligase
activity is abolished, bound TRF2 as efficiently as the wild-type
form, indicating that the ubiquitin-ligase activity of RNF4 is not
essential for the interaction with TRF2 (Fig. 4A). To further support
the direct interaction between RNF4 and TRF2, we performed GST
pull-down experiments with purified proteins. GST-RNF4, but not
the control GST, precipitated His-TRF2 (Fig. 4B). To investigate
whether the sumoylation of TRF2 enhances the interaction
between TRF2 and RNF4, HEK293 cells expressing Flag-TRF2,
Myc-PIAS1 and His-SUMO-2 were subjected to immunoprecipita-
tion with anti-Flag antibody. After washing with lysis buffer, the
anti-Flag immunoprecipitates were incubated with lysates that
had been prepared from cells expressing V5-RNF4, followed by
immunoblotting with anti-V5 antibody. The amount of V5-RNF4
was greatly increased in the anti-Flag immunoprecipitates when
PIAS1 and SUMO-2 were co-expressed (Fig. 4C), indicating that
non-SUMOylated form of TRF2 and RNF4 form complex efficiently
in the presence of PIAS and SUMO.
We next examined whether SUMO-modified TRF2 is
ubiquitinated by RNF4 and subsequently degraded by the protea-
some. Co-transfection of Flag-TRF2, Myc-PIAS1 and V5-SUMO-1
or V5-SUMO-2 resulted in the appearance of several bands corre-
sponding to SUMO-conjugated TRF2 (Fig. 4D). When RNF4 was
co-expressed, the levels of SUMO-conjugated TRF2 were reduced
for both SUMO-1 and SUMO-2. However, this reduction was res-
cued by treating cells with MG132 (Fig. 4D). We note that the
levels of unmodified TRF2 were not affected in various conditions.
These results indicate that RNF4 targets SUMO-modified TRF2 for
ubiquitin-dependent proteasomal degradation. To further verify
that RNF4 directly mediates the ubiquitination of SUMO-
modified TRF2, we performed RNF4 depletion experiments using
a pool of siRNA duplexes (Fig. 4E) and determined the effect of
RNF4 depletion on the ubiquitination of TRF2. RNF4-depleted cells
were co-transfected with Flag-TRF2 and HA-ubiquitin prior to
MG132 treatment and subjected to immunoprecipitation to detect
ubiquitin-modified TRF2. Ubiquitin conjugates of TRF2 were read-
ily detected in the presence of MG132 (Fig. 4F). The amounts of
ubiquitinated TRF2 were greatly reduced by RNF4 depletion, sug-
gesting that RNF4 promotes the ubiquitination of TRF2.4. Discussion
TRF2 is the shelterin protein that protects chromosome ends by
facilitating their organization into the protective capping structure
[10,11] and functions as a negative regulator of telomere length by
controlling the access of telomerase [38]. Experimental inhibition
of TRF2 results in telomere dysfunction, which in turn activates a
DNA damage response at telomeres [12,13]. Therefore, the levels
of TRF2 at telomeres should be tightly regulated to ensure proper
function of telomeres. In this work, we show that TRF2 interacts
with and is sumoylated by PIAS1 in mammalian cells. Our results
demonstrate that SUMO-conjugated TRF2 is preferentiallyubiquitinated by RNF4 and subsequently degraded by the protea-
some, suggesting that TRF2 sumoylation plays a crucial role for
regulating the levels of TRF2 at telomeres.
Sumoylation often, but not always, occurs on acceptor lysines
within a defined consensus motif, WKxE (Wdenotes a hydropho-
bic residue and x is any amino acid) [39]. Human TRF2 contains
three consensus sumoylation sites, IK140TE, LK245SE, and RK333DE.
These three lysine residues have been shown to be sumoylated by
MMS21, a SUMO ligase of the SMC5/6 complex [24]. We thus
investigated whether these sites are also sumoylated by PIAS1.
Mutations of all three potential sites (TRF2DSUMO) had no
impact on PIAS1-dependent sumoylation of TRF2 (Suppl.
Fig. S4A). Furthermore, mutation did not affect the levels of
SUMO-conjugated TRF2 that is stabilized by proteasome inhibi-
tion (Suppl. Fig. S4B). These results suggest the presence of
non-consensus sites for PIAS1-mediated TRF2 sumoylation.
Although sumoylation sites of PIAS1 have not been determined
in this study, some acceptor sites have been identified that do
not contain this consensus motif [21].
Although sumoylation is important for the degradation of some
target proteins, SUMO conjugation generally modifies protein
function by altering subcellular localization, activity or protein–
protein interactions [21]. Previously, it was reported that sumoyla-
tion of TRF1 and TRF2 by MMS21 is required for the recruitment of
telomeres to PML bodies in ALT cells [24]. Thus, we examined
whether PIAS1-mediated sumoylation affects the ALT-associated
PML body (APB) formation in ALT cells. APB formation was ana-
lyzed by examining co-localization of TRF2 and PML. Depletion of
PIAS1 did not block the recruitment of telomeres to PML bodies
in U2OS cells (Suppl. Fig. S5), suggesting that PIAS1-dependent
TRF2 sumoylation has no effect on the APB formation in ALT cells,
but instead sumoylated TRF2 is targeted for ubiquitin-dependent
proteolysis.
This study demonstrates that SUMO-conjugated TRF2 accumu-
lates upon proteasome inhibition by MG132. Whereas SUMO-2
and SUMO-3 contain a single lysine residue that is used for SUMO
chain formation, SUMO-1 acts as a chain terminator by attaching to
the ends of polySUMO-2/3 chains [23]. Although it is difficult to
distinguish the SUMO-1 on the polySUMO-2/3 chains from multi-
ple monosumoylation in vivo, MG132 stabilizes TRF2 that is conju-
gated by both SUMO-1 and SUMO-2/3. By contrast, the levels of
unmodified TRF2 were not affected by proteasome inhibition.
These findings suggest that SUMO conjugation regulates the stabil-
ity of TRF2 by targeting this protein for proteasomal degradation.
We also showed that SUMO-conjugated TRF2 is ubiquitinated in
the presence of MG132. Under the conditions in which sumoyla-
tion is inhibited by overexpression of SENP1 or depletion of
Ubc9, the amounts of ubiquitinated TRF2 were reduced, suggesting
that SUMO conjugation is required for ubiquitin-dependent degra-
dation of TRF2.
RNF4 is a mammalian SUMO-targeted ubiquitin ligase that con-
tains SIM and RING domains and interacts with several SUMO-
conjugated proteins to promote ubiquitination [30]. Consistently,
RNF4 interacts with TRF2 in a SUMO-dependent manner and
enhances the ubiquitination of SUMO-conjugated TRF2. Depletion
of RNF4 led to a clear reduction in the level of ubiquitinated TRF2,
indicating that RNF4 is critical for TRF2 ubiquitination. We also
showed that RNF4 regulates the levels of SUMO-conjugated TRF2.
The amounts of both SUMO-1- and SUMO-2/3-conjugated TRF2
were decreased upon RNF4 overexpression. Collectively, our data
demonstrate that RNF4 serves as a STUbL that targets sumoylated
TRF2 for ubiquitination. TRF2 has also been shown to interact with
and be ubiquitinated by Siah1, the first factor identified as an ubiq-
uitin ligase for TRF2. Siah1 is transcriptionally induced by p53 [20].
Functional inhibition of TRF2 results in dysfunctional telomeres that
induce cellular senescence through the ATM- and p53-mediated
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Fig. 4. SUMO-conjugated TRF2 interacts with and is ubiquitinated by RNF4. (A) HEK293 cells were co-transfected with Flag-TRF2 and V5-RNF4 (or V5-RNF4C132,135S) and
subjected to immunoprecipitation with anti-V5 antibody, followed by immunoblotting with anti-Flag antibody. Molecular mass makers are shown in kilodaltons. (B) GST or
GST-RNF4 were immobilized on glutathione-Sepharose and incubated with purified His-TRF2 that had been expressed in bacteria. Bound proteins were detected by
immunoblotting with anti-TRF2 antibody. The purified GST-fused and His-tagged proteins were visualized by Coomassie staining. (C) HEK293 cells were co-transfected with
Flag-TRF2, Myc-PIAS1 and His-SUMO-2 and subjected to immunoprecipitation with anti-Flag antibody. After washed with lysis buffer, the immunoprecipitates were
incubated with lysates that had been prepared from cells expressing V5-RNF4. Bound proteins were detected by immunoblotting with anti-V5 antibody. (D) HEK293 cells
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3284 J. Her et al. / FEBS Letters 589 (2015) 3277–3286pathway [40]. Thesefindings led to amodel thatp53-inducible Siah1
plays a key role in this feedback loop mechanism by targeting TRF2
for ubiquitination and proteasomal degradation [20]. In this work,
we provide evidence that RNF4 promotes the ubiquitination of
sumoylated TRF2. On the basis of the results presented in this study,
we propose a model for the regulation of TRF2 stability via a cross-
talk between sumoylation and ubiquitination (Fig. 5). TRF2 binding
to telomeres is required to maintain telomeres in a protective con-
figuration. Sumoylation by PIAS1may induce a release of TRF2 from
telomeres. Alternatively, PIAS1may preferentially interact with and
sumoylate the telomere-unbound form of TRF2. The resultingtelomere-dissociated TRF2 is then rapidly ubiquitinated by RNF4
and degraded by the proteasome. This sequential modification of
TRF2 prevents reassociation of TRF2 with telomeres. Reassembly
of telomeres with TRF2 into a protective capping structure may
occur with newly synthesized TRF2. Because TRF2 is essential for
protection of chromosome ends, it is likely that only a small portion
of TRF2would be sumoylated and ubiquitinated for its turnover.We
also found that TRF1 is sumoylated by PIAS1 and that sumoylated
TRF1 is accumulated by theMG132 treatment (Suppl. Fig. S6). Thus,
it will be interesting to investigate how sumoylation of TRF1 by
PIAS1 influences telomere function.
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Fig. 5. Model for the regulation of TRF2 stability at telomeres via a cross-talk
between sumoylation and ubiquitination. TRF2 is modified by SUMO-1 and SUMO-
2/3 in a PIAS1-dependent manner. Sumoylation by PIAS1 may release TRF2 from
telomeres. The telomere-unbound form of TRF2 is preferentially ubiquitinated by
RNF4 and subsequently degraded by the proteasome. Sequential post-translational
modification of TRF2 such as sumoylation and ubiquitination plays important roles
in regulating the levels of TRF2 at telomeres.
J. Her et al. / FEBS Letters 589 (2015) 3277–3286 3285In conclusion, our data provide evidence for a previously
unknown function of TRF2 sumoylation. We show that RNF4 is a
SUMO-targeted ubiquitin ligase that targets TRF2 for ubiquitina-
tion. Thus, PIAS1 functions in concert with RNF4 in modulating
the stability of TRF2. Although many important questions about
the physiological significance of multiple SUMO E3 ligases for
TRF2 and how PIAS1-mediated sumoylation is regulated under
diverse physiological conditions remain to be resolved, our results
demonstrate that post-translational modification of TRF2 by PIAS1
and RNF4 represents a new pathway for maintaining proper func-
tion of TRF2 at telomeres.
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